Aflibercept and Brolucizumab in Diabetic Macular Edema: A Focused Review of Efficacy, Safety, and Clinical Considerations

<b>Background/Objectives:</b> Diabetic macular edema (DME) are major causes of visual impairment worldwide, with vascular endothelial growth factor (VEGF) playing a central role in disease pathogenesis. Intravitreal anti-VEGF therapy is the current standard of care for center-involving DME. <b>Metho...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Ana Maria Dascalu, Catalin Cicerone Grigorescu, Ece Ergin, Cristina Alexandrescu, Dan Dumitrescu, Marina Ionela Nedea, Bogdan Mihai Cristea, Dragos Serban, Laura Carina Tribus, Tudor Mihai Badescu
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2026-02-01
Edice:	Biomedicines
Témata:	diabetic retinopathy diabetic macular edema anti-VEGF therapy aflibercept brolucizumab intravitreal injections
On-line přístup:	https://www.mdpi.com/2227-9059/14/3/501
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!